Therefore, augmentation therapy with AAT in T2D subjects may have a double potential therapeutic impact by protecting pancreatic islets from hIAPP-induced islet dysfunction and by ameliorating obesity and insulin resistance. The gene discussed is SERPINA1; the disease is type 2 diabetes mellitus.